U.S. Markets close in 5 hrs 8 mins

Peregrine Pharmaceuticals, Inc. (PPHM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.120.00 (0.00%)
As of 10:50AM EDT. Market open.
People also watch

Peregrine Pharmaceuticals, Inc.

14282 Franklin Avenue
Tustin, CA 92780
United States

Full Time Employees319

Key Executives

Mr. Steven W. KingPres, CEO & Director873.31kN/A53
Mr. Paul J. Lytle CPAChief Financial Officer597.92kN/A49
Mr. Mark R. Ziebell J.D.VP, Gen. Counsel & Corp. Sec.518.16kN/A53
Dr. Shelley P. M. Fussey Ph.D.VP of Intellectual Property365.15kN/A51
Mr. Joseph S. Shan M.P.H.VP of Clinical & Regulatory Affairs447.78kN/A44
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment of cancer in the United States. Its lead immunotherapy candidate is bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company also provides integrated current good manufacturing practices services from cell line development to commercial bio manufacturing for its third-party customers. In addition, its services comprise cGMP clinical and commercial manufacturing utilizing stainless steel and single use bioreactor technology, purification, bulk packaging, stability testing, regulatory strategy, and support. The company has license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; and Lonza Biologics, as well as collaboration agreement with National Comprehensive Cancer Network, AstraZeneca PLC, and Memorial Sloan Kettering Cancer Center. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

Corporate Governance

Peregrine Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.